CY1116874T1 - Δοσολογικο σχημα για τη χορηγηση ενος cd19xcd3 αμφιειδικου αντισωματος - Google Patents
Δοσολογικο σχημα για τη χορηγηση ενος cd19xcd3 αμφιειδικου αντισωματοςInfo
- Publication number
- CY1116874T1 CY1116874T1 CY20151100956T CY151100956T CY1116874T1 CY 1116874 T1 CY1116874 T1 CY 1116874T1 CY 20151100956 T CY20151100956 T CY 20151100956T CY 151100956 T CY151100956 T CY 151100956T CY 1116874 T1 CY1116874 T1 CY 1116874T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibody
- dose
- cd19xcd3
- administration
- amphiphilic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5052—Cells of the immune system involving B-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ecology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε μια μέθοδο για τον υπολογισμό (ανάλυση) του κινδύνου δυνητικών δυσμενών επιπτώσεων για έναν ασθενή άνθρωπο μεσολαβούμενων από τη χορήγηση ενός CD19xCD3 αμφιειδικού αντισώματος στο ρηθέντα ασθενή η οποία μέθοδος περιλαμβάνει τον καθορισμό του λόγου Β-κυττάρων προς Τ-λεμφοκύτταρα του ρηθέντος ασθενή, όπου ένας λόγος περίπου 1:5 ή χαμηλότερος είναι ενδεικτικός ενός κινδύνου δυνητικών δυσμενών επιπτώσεων για το ρηθέντα ασθενή. Αναλόγως, η παρούσα εφεύρεση αναφέρεται σε μια μέθοδο (δοσολογικό σχήμα) για τη χορήγηση ενός CD19xCD3 αμφιειδικού αντισώματος σε έναν ασθενή άνθρωπο που έχει ένα λόγο Β-κυττάρων: Τ-λεμφοκύτταρα περίπου 1:5 ή χαμηλότερο, η οποία μέθοδος περιλαμβάνει (a) χορήγηση μιας πρώτης δόσης του ρηθέντος αντισώματος για μια πρώτη χρονική περίοδο- και διαδοχικά (b) χορήγηση μιας δεύτερης δόσης του ρηθέντος αντισώματος για μια δεύτερη χρονική περίοδο, όπου η ρηθείσα δεύτερη δόση υπερβαίνει τη ρηθείσα πρώτη δόση. Σε μερικές ενσωματώσεις, μια τρίτη δόση του ρηθέντος αντισώματος χορηγείται για μια τρίτη χρονική περίοδο. Αυτό το δοσολογικό σχήμα μπορεί να εφαρμοστεί σε μεθόδους για τη θεραπεία κακοηθών CD 19 θετικών λεμφοκυττάρων ή για τη βελτίωση ή/και πρόληψη μιας δυσμενούς επίπτωσης μεσολαβούμενης από τη χορήγηση του ρηθέντος αμφιειδικού αντισώματος. Η παρούσα εφεύρεση αναφέρεται επίσης στη χρησιμοποίηση ενός CD19xCD3 αμφιειδικού αντισώματος για την παρασκευή μιας φαρμακευτικής σύνθεσης προς χρήση σε μια μέθοδο της παρούσας εφεύρεσης. Επίσης αποκαλύπτεται μια φαρμακευτική συσκευασία ή κιτίο που περιλαμβάνει μια πρώτη δόση και μια δεύτερη δόση και προαιρετικώς μια τρίτη δόση του ρηθέντος αντισώματος όπως ορίζεται στις
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25529009P | 2009-10-27 | 2009-10-27 | |
EP09174104 | 2009-10-27 | ||
EP10771102.0A EP2493503B2 (en) | 2009-10-27 | 2010-10-27 | Dosage regimen for administering a cd19xcd3 bispecific antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116874T1 true CY1116874T1 (el) | 2017-04-05 |
Family
ID=43921378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100956T CY1116874T1 (el) | 2009-10-27 | 2015-10-26 | Δοσολογικο σχημα για τη χορηγηση ενος cd19xcd3 αμφιειδικου αντισωματος |
Country Status (27)
Country | Link |
---|---|
US (2) | US8840888B2 (el) |
EP (1) | EP2493503B2 (el) |
JP (2) | JP6092625B2 (el) |
KR (2) | KR101841781B1 (el) |
CN (2) | CN107227335A (el) |
AU (1) | AU2010311559B2 (el) |
BR (1) | BR112012009778A2 (el) |
CA (1) | CA2774919C (el) |
CY (1) | CY1116874T1 (el) |
DK (1) | DK2493503T4 (el) |
ES (1) | ES2552655T5 (el) |
HK (1) | HK1172828A1 (el) |
HR (1) | HRP20151196T4 (el) |
HU (1) | HUE025759T2 (el) |
IL (1) | IL219301A (el) |
ME (1) | ME02947B (el) |
MX (1) | MX2012004880A (el) |
NZ (1) | NZ598732A (el) |
PL (1) | PL2493503T5 (el) |
PT (1) | PT2493503E (el) |
RS (1) | RS54655B2 (el) |
RU (1) | RU2548746C2 (el) |
SG (2) | SG10201406533RA (el) |
SI (1) | SI2493503T2 (el) |
SM (1) | SMT201500267B (el) |
WO (1) | WO2011051307A1 (el) |
ZA (1) | ZA201201774B (el) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME02363B (me) * | 2008-11-07 | 2016-06-20 | Amgen Res Munich Gmbh | Liječenje akutne limfoblastične leukemije |
EP2918604B1 (en) * | 2008-11-07 | 2017-12-20 | Amgen Research (Munich) GmbH | Treatment of pediatric acute lymphoblastic leukemia |
RS54655B2 (sr) * | 2009-10-27 | 2021-04-29 | Amgen Res Munich Gmbh | Dozni režim za primenu cd19xcd3 bispecifičnog antitela |
SI2632954T2 (sl) * | 2010-10-27 | 2021-11-30 | Amgen Research (Munich) Gmbh | Sredstva in postopki za zdravljenje dlbcl |
US10130638B2 (en) | 2010-11-10 | 2018-11-20 | Amgen Research (Munich) Gmbh | Prevention of adverse effects caused by CD3 specific binding domains |
JP6276175B2 (ja) | 2011-04-28 | 2018-02-07 | アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング | 潜在的有害作用リスクのある患者にCD19xCD3二特異性抗体を投与するための投薬レジメン |
EP2943511B1 (en) | 2013-01-14 | 2019-08-07 | Xencor, Inc. | Novel heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US9486475B2 (en) | 2013-02-08 | 2016-11-08 | Amgen Research (Munich) Gmbh | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains |
JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
CN103275225A (zh) * | 2013-05-10 | 2013-09-04 | 洪建� | 高亲合力抗cd31/cd146双特异单克隆抗体及其应用 |
CN104342453A (zh) * | 2013-08-06 | 2015-02-11 | 深圳先进技术研究院 | 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用 |
SG10202008629XA (en) | 2014-03-28 | 2020-10-29 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
RU2568910C2 (ru) * | 2014-04-18 | 2015-11-20 | Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") | Фармацевтические композиции на основе флексибоди против cd3*cd19 для лечения в-клеточных заболеваний |
HUE042407T2 (hu) | 2014-05-30 | 2019-06-28 | Amgen Res Munich Gmbh | B-prekurzor akut limfoblasztos leukémiában szenvedõ betegek kockázati besorolása |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
IL252480B2 (en) | 2014-11-26 | 2023-12-01 | Xencor Inc | Heterodimeric antibodies that bind CD3 and tumor antigens |
JP2017536830A (ja) | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd3及びcd38に結合するヘテロ二量体抗体 |
CA2991799A1 (en) | 2015-07-15 | 2017-01-19 | Zymeworks Inc. | Drug-conjugated bi-specific antigen-binding constructs |
RS62260B1 (sr) * | 2015-08-21 | 2021-09-30 | Morphosys Ag | Kombinacije i njihova upotreba |
MA44909A (fr) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk |
CN114470192A (zh) | 2015-10-13 | 2022-05-13 | 优瑞科生物技术公司 | 对人类cd19具有专一性的抗体药剂和其用途 |
RU2651776C2 (ru) * | 2015-12-01 | 2018-04-23 | Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") | Биспецифические антитела против cd3*cd19 |
US11623957B2 (en) | 2015-12-07 | 2023-04-11 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
JOP20170091B1 (ar) * | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية |
IL263542B1 (en) | 2016-06-14 | 2024-06-01 | Xencor Inc | Bispecific antibodies inhibit immunological checkpoint |
WO2018005706A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
KR20190120782A (ko) | 2017-02-20 | 2019-10-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
SG11201907645PA (en) * | 2017-02-20 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding cd123, nkg2d and cd16 |
JP7185696B2 (ja) | 2017-09-22 | 2022-12-07 | ウーシー バイオロジクス アイルランド リミテッド | 新規な二重特異性cd3/cd19ポリペプチド複合体相互参照 |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CA3082383A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
AU2018382966A1 (en) | 2017-12-14 | 2020-04-09 | F. Hoffmann-La Roche Ag | Use of a CEA CD3 bispecific antibody and a PD-1 axis binding antagonist in a dosage regime to treat cancer |
US11319355B2 (en) | 2017-12-19 | 2022-05-03 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
CN108017717B (zh) | 2018-01-24 | 2019-08-16 | 首都医科大学宣武医院 | 一种用于体外高效定向扩增的嵌合抗原受体及其应用 |
AU2019218136A1 (en) | 2018-02-08 | 2020-08-13 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
US11505595B2 (en) | 2018-04-18 | 2022-11-22 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains |
JP2021521784A (ja) | 2018-04-18 | 2021-08-30 | ゼンコア インコーポレイテッド | IL−15/IL−15RaFc融合タンパク質とPD−1抗原結合ドメインを含むPD−1標的化ヘテロダイマー融合タンパク質およびそれらの使用 |
CN112771075A (zh) * | 2018-07-30 | 2021-05-07 | 安进研发(慕尼黑)股份有限公司 | 结合至cd33和cd3的双特异性抗体构建体的延长施用 |
WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
SG11202109406TA (en) | 2019-03-01 | 2021-09-29 | Xencor Inc | Heterodimeric antibodies that bind enpp3 and cd3 |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
IL300666A (en) | 2020-08-19 | 2023-04-01 | Xencor Inc | ANTI–CD28 COMPOSITIONS |
CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Cd3及びgpc3に結合するヘテロ二量体抗体 |
WO2023061419A1 (en) * | 2021-10-12 | 2023-04-20 | Concept To Medicine Biotech Co., Ltd. | Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
NZ507381A (en) * | 1998-04-21 | 2003-12-19 | Micromet Ag | CD19xCD3 specific polypeptides and uses thereof |
AU2004242846A1 (en) * | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
US7771999B2 (en) * | 2004-04-28 | 2010-08-10 | Vaxdesign Corp. | Disease model incorporation into an artificial immune system (AIS) |
AU2006326727A1 (en) * | 2005-12-16 | 2007-06-21 | Amgen Research (Munich) Gmbh | Means and methods for the treatment of tumorous diseases |
CN101331151A (zh) * | 2005-12-16 | 2008-12-24 | 麦克罗梅特股份公司 | 治疗肿瘤性疾病的方式和方法 |
CN101687915B8 (zh) | 2007-04-03 | 2018-08-03 | 安进研发(慕尼黑)股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
BRPI0809594A2 (pt) | 2007-04-03 | 2019-08-27 | Micromet Ag | polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s) |
ME02363B (me) | 2008-11-07 | 2016-06-20 | Amgen Res Munich Gmbh | Liječenje akutne limfoblastične leukemije |
RS54655B2 (sr) * | 2009-10-27 | 2021-04-29 | Amgen Res Munich Gmbh | Dozni režim za primenu cd19xcd3 bispecifičnog antitela |
JP6276175B2 (ja) | 2011-04-28 | 2018-02-07 | アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング | 潜在的有害作用リスクのある患者にCD19xCD3二特異性抗体を投与するための投薬レジメン |
-
2010
- 2010-10-27 RS RS20150738A patent/RS54655B2/sr unknown
- 2010-10-27 ES ES10771102T patent/ES2552655T5/es active Active
- 2010-10-27 PL PL10771102T patent/PL2493503T5/pl unknown
- 2010-10-27 US US13/504,665 patent/US8840888B2/en active Active
- 2010-10-27 EP EP10771102.0A patent/EP2493503B2/en active Active
- 2010-10-27 AU AU2010311559A patent/AU2010311559B2/en active Active
- 2010-10-27 KR KR1020127009959A patent/KR101841781B1/ko active IP Right Grant
- 2010-10-27 MX MX2012004880A patent/MX2012004880A/es active IP Right Grant
- 2010-10-27 RU RU2012121895/15A patent/RU2548746C2/ru active
- 2010-10-27 CA CA2774919A patent/CA2774919C/en active Active
- 2010-10-27 PT PT107711020T patent/PT2493503E/pt unknown
- 2010-10-27 CN CN201710532711.7A patent/CN107227335A/zh active Pending
- 2010-10-27 SG SG10201406533RA patent/SG10201406533RA/en unknown
- 2010-10-27 KR KR1020187007543A patent/KR102406407B1/ko active IP Right Grant
- 2010-10-27 JP JP2012535798A patent/JP6092625B2/ja active Active
- 2010-10-27 SG SG2012018982A patent/SG179204A1/en unknown
- 2010-10-27 SI SI201031057T patent/SI2493503T2/sl unknown
- 2010-10-27 NZ NZ598732A patent/NZ598732A/en unknown
- 2010-10-27 BR BR112012009778A patent/BR112012009778A2/pt not_active Application Discontinuation
- 2010-10-27 ME MEP-2017-301A patent/ME02947B/me unknown
- 2010-10-27 CN CN201080048898XA patent/CN102711822A/zh active Pending
- 2010-10-27 WO PCT/EP2010/066207 patent/WO2011051307A1/en active Application Filing
- 2010-10-27 HU HUE10771102A patent/HUE025759T2/en unknown
- 2010-10-27 DK DK10771102.0T patent/DK2493503T4/da active
-
2012
- 2012-03-12 ZA ZA201201774A patent/ZA201201774B/en unknown
- 2012-04-19 IL IL219301A patent/IL219301A/en active IP Right Grant
-
2013
- 2013-01-02 HK HK13100007.6A patent/HK1172828A1/xx active IP Right Maintenance
-
2014
- 2014-09-19 US US14/491,459 patent/US10662243B2/en active Active
-
2015
- 2015-10-26 CY CY20151100956T patent/CY1116874T1/el unknown
- 2015-10-28 SM SM201500267T patent/SMT201500267B/it unknown
- 2015-11-09 HR HRP20151196TT patent/HRP20151196T4/hr unknown
-
2016
- 2016-12-06 JP JP2016236436A patent/JP6476159B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116874T1 (el) | Δοσολογικο σχημα για τη χορηγηση ενος cd19xcd3 αμφιειδικου αντισωματος | |
CY1123688T1 (el) | Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20 | |
RU2708374C2 (ru) | Комбинированная терапия для лечения рака | |
MX354371B (es) | Régimen de dosificación para administrar un anticuerpo biespecífico cd19xcd3 a pacientes en riesgo de efectos adversos potenciales. | |
CY1123764T1 (el) | Τετραϋδροβιοπτερινη για θεραπεια καταστασεων που σχετιζονται με αυξημενα επιπεδα φαινυλαλανινης | |
CY1120014T1 (el) | Αντισωματα συνδεσης πρωτοϊνιδιου και χρηση αυτων σε θεραπευτικες και διαγνωστικες μεθοδους για ασθενεια parkinson, ανοια με σωματα lewy και αλλες αλφα-συνουκλεϊνοπαθειες | |
BR112017024777A2 (pt) | uso de uma composiçao farmacêutica e de um antibiótico não absorvível para tratamento de transtorno do espectro autista referência cruzada a pedidos relacionados? | |
CY1116727T1 (el) | Θεραπεια πολλαπλης σκληρυνσης me laquinimod | |
EA201290171A1 (ru) | Вводимые перорально кортикостероидные композиции | |
EA201300016A1 (ru) | Конъюгаты антител человека против тканевого фактора с лекарственными препаратами | |
RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
EA201170669A1 (ru) | Лечение пирфенидоном пациентов с атипичной функцией печени | |
CY1121530T1 (el) | Μεθοδοι θεραπειας της στοματικης βλεννογονιτιδας | |
SG179027A1 (en) | Dosage regimen for administering an epcamxcd3 bispecific antibody | |
EA201500432A1 (ru) | Соединения боронатного эфира и его фармацевтические составы | |
ATE485037T1 (de) | Krebsbehandlung mittels fts und 2-deoxyglucose | |
BR112014027010A2 (pt) | uso de laquinimod de alta dose para tratamento de esclerose múltipla | |
JP2019532047A5 (el) | ||
EA201690005A1 (ru) | Состав с модифицированной кинетикой высвобождения | |
JP2019530706A5 (el) | ||
TR201819662T4 (tr) | Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi. | |
MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
EA201390417A1 (ru) | Антидиабетические твердые фармацевтические композиции | |
EA201000990A1 (ru) | Лечение дисменореи путем трансдермального введения нестероидных противовоспалительных лекарственных средств | |
CY1120847T1 (el) | Σχημα αγωγης ενωσης τιακουμικινης |